Antibiotic resistance and vaccination in patients with urinary tract infection
Journal Title: Нирки - Year 2018, Vol 7, Issue 1
Abstract
Limited in experience of using uroantiseptics, even those manufactured in European countries, such as Furamag and Macmiror, excessive use of antibiotics, which causes antibiotic resistance in the EU countries and form resistance to antibiotics. The problem of treatment resistant, recurrent infections of the urinary tract and asymptomatic bacteriuria can be solved with vaccinotherapy. Urivac may recommend as an independent option or in combination with prophylactic treatment with uroanticeptic and/or phytomedicine.
Authors and Affiliations
D. D. Ivanov
Keywords
Related Articles
- EP ID EP265050
- DOI 10.22141/2307-1257.7.1.2018.122213
- Views 74
- Downloads 0
Pathophysiological and Methodological Aspects of Determining Renal Functional Reserve in Clinical Nephrology
The article pathogenetically substantiates the feasibility of using methods for determining functional renal reserve through salt and water loading of 0.5% sodium chloride in an amount of 0.5 % of the body weight in pati...
Effective treatment and prevention of recurrent urinary tract infections by using Cysto-aurin®, a Solidago virgaurea preparation
We conducted a study of clinical and laboratory efficacy, as well as evaluated the effect on the quality of life of intermittent therapy with Cysto-aurin drug in 96 patients with recurrent urinary tract infection (UTI)....
Next Step in Chronic Kidney Disease Therapy
Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers are the basis of renoprotection therapy in chronic kidney disease. Parallel to decrease of glomerular filtration rate, there is an increase in the ac...
Renin-Angiotensin System Blockers and Renal Functional Reserve. Is There a Limit of Renoprotection?
Renin-angiotensin system (RAS) blockers (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, direct renin inhibitor) have a renoprotective effect in the presence of preserved glomerular filtration ra...
Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice
Recently, the European Medicines Agency approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney dis...